-

MindMed to Report Q3 2025 Financial Results on November 6, 2025

NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that it will host a live webcast at 4:30 p.m. EST on Thursday, November 6, 2025 to report financial results for the third quarter ended September 30, 2025, and discuss recent business updates.

Listeners can register for the webcast via this link. Analysts wishing to participate in the question and answer session should use this link. A replay of the webcast will be available via the Investor Relations section of the MindMed website, ir.mindmed.co, and archived for at least 30 days after the webcast. Those who plan on participating are advised to join 15 minutes prior to the start time.

About MindMed

MindMed is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. Our mission is to be the global leader in the development and delivery of treatments that unlock new opportunities to improve patient outcomes. We are developing a pipeline of innovative product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways that play key roles in brain health. MindMed trades on NASDAQ under the symbol MNMD.

Contacts

Investors:
Gitanjali Jain
VP, Head of Investor Relations
ir@mindmed.co

Media:
media@mindmed.co

Industry:

Mind Medicine (MindMed) Inc.

NASDAQ:MNMD
Release Versions
English

Contacts

Investors:
Gitanjali Jain
VP, Head of Investor Relations
ir@mindmed.co

Media:
media@mindmed.co

More News From Mind Medicine (MindMed) Inc.

Definium Therapeutics, Inc. Announces Closing of $805 Million Upsized Public Offering, Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares

NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (Nasdaq: DFTX) (the “Company” or “Definium”), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced the closing of its previously announced underwritten public offering of 23,676,471 common shares, without par value, which includes the exercise in full by the underwriters of their option to purchase 3,088,23...

Definium Therapeutics, Inc. Announces Pricing of $700 Million Upsized Public Offering

NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (Nasdaq: DFTX) (the “Company” or “Definium”), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced the pricing of an underwritten public offering of 20,588,236 common shares, without par value, at a public offering price of $34.00 per common share. The gross proceeds to Definium from the offering, before de...

Definium Therapeutics, Inc. Announces Proposed Public Offering

NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (Nasdaq: DFTX) (the “Company” or “Definium”), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced that it intends to offer and sell, subject to market conditions, $500 million of its common shares and, to certain investors, pre-funded warrants to purchase common shares in an underwritten public offering. I...
Back to Newsroom